JP2005520797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005520797A5 JP2005520797A5 JP2003552762A JP2003552762A JP2005520797A5 JP 2005520797 A5 JP2005520797 A5 JP 2005520797A5 JP 2003552762 A JP2003552762 A JP 2003552762A JP 2003552762 A JP2003552762 A JP 2003552762A JP 2005520797 A5 JP2005520797 A5 JP 2005520797A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- optionally substituted
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000005843 halogen group Chemical group 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000003342 alkenyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- -1 hydrate Chemical class 0.000 claims 13
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 125000004104 aryloxy group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 5
- 125000003435 aroyl group Chemical group 0.000 claims 5
- 125000005333 aroyloxy group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000005171 Dysmenorrhea Diseases 0.000 claims 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 206010049589 Afterbirth pain Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 2
- 206010006811 Bursitis Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000010040 Sprains and Strains Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- XPADLLDUINGAJK-UHFFFAOYSA-N 3-[[4-(3-chloro-4-fluorophenyl)phenyl]methyl]-4-(difluoromethoxy)-1-methylquinolin-2-one Chemical compound O=C1N(C)C2=CC=CC=C2C(OC(F)F)=C1CC(C=C1)=CC=C1C1=CC=C(F)C(Cl)=C1 XPADLLDUINGAJK-UHFFFAOYSA-N 0.000 claims 1
- WRKWOOLOGLUCHA-UHFFFAOYSA-N 3-[[4-(3-chloro-4-fluorophenyl)phenyl]methyl]-4-hydroxy-1-methylquinolin-2-one Chemical compound O=C1N(C)C2=CC=CC=C2C(O)=C1CC(C=C1)=CC=C1C1=CC=C(F)C(Cl)=C1 WRKWOOLOGLUCHA-UHFFFAOYSA-N 0.000 claims 1
- WLPAZQBTHCCNGO-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)sulfanylphenyl]methyl]-4-hydroxy-1-methylquinolin-2-one Chemical compound O=C1N(C)C2=CC=CC=C2C(O)=C1CC(C=C1)=CC=C1SC1=CC=C(Cl)C=C1 WLPAZQBTHCCNGO-UHFFFAOYSA-N 0.000 claims 1
- ISJPFZZQVVWYBW-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)sulfonylphenyl]methyl]-4-hydroxy-1-methylquinolin-2-one Chemical compound O=C1N(C)C2=CC=CC=C2C(O)=C1CC(C=C1)=CC=C1S(=O)(=O)C1=CC=C(Cl)C=C1 ISJPFZZQVVWYBW-UHFFFAOYSA-N 0.000 claims 1
- YFOAUBSMNOQETP-UHFFFAOYSA-N 4-amino-3-[[4-(3-chloro-4-fluorophenyl)phenyl]methyl]-1-methylquinolin-2-one Chemical compound O=C1N(C)C2=CC=CC=C2C(N)=C1CC(C=C1)=CC=C1C1=CC=C(F)C(Cl)=C1 YFOAUBSMNOQETP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000004623 Colonic Diverticulitis Diseases 0.000 claims 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- OFAIGZWCDGNZGT-UHFFFAOYSA-N caramiphen Chemical compound C=1C=CC=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 OFAIGZWCDGNZGT-UHFFFAOYSA-N 0.000 claims 1
- 229960004160 caramiphen Drugs 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 230000001120 cytoprotective effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003559 enprostil Drugs 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims 1
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 claims 1
- 229960005249 misoprostol Drugs 0.000 claims 1
- 229960005016 naphazoline Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 230000003533 narcotic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 229960001528 oxymetazoline Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 229960003436 pentoxyverine Drugs 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 229960003893 phenacetin Drugs 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 229960000395 phenylpropanolamine Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960000786 propylhexedrine Drugs 0.000 claims 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 201000007183 prothrombin deficiency Diseases 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- NMAOJFAMEOVURT-RTKIROINSA-N rosaprostol Chemical compound CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC(O)=O NMAOJFAMEOVURT-RTKIROINSA-N 0.000 claims 1
- 229950003055 rosaprostol Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940083037 simethicone Drugs 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 229960000833 xylometazoline Drugs 0.000 claims 1
- 0 *C(Cc1c2c(C(*)=C3Cc4ccccc4)ccc1)N2C3=O Chemical compound *C(Cc1c2c(C(*)=C3Cc4ccccc4)ccc1)N2C3=O 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34043901P | 2001-12-14 | 2001-12-14 | |
| PCT/CA2002/001914 WO2003051878A1 (en) | 2001-12-14 | 2002-12-11 | Quinolinones as prostaglandin receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005520797A JP2005520797A (ja) | 2005-07-14 |
| JP2005520797A5 true JP2005520797A5 (enExample) | 2006-03-30 |
Family
ID=23333355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552762A Pending JP2005520797A (ja) | 2001-12-14 | 2002-12-11 | プロスタグランジン受容体リガンドとしてのキノリノン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7348433B2 (enExample) |
| EP (1) | EP1458718B1 (enExample) |
| JP (1) | JP2005520797A (enExample) |
| AT (1) | ATE343577T1 (enExample) |
| AU (1) | AU2002350315B2 (enExample) |
| CA (1) | CA2469048A1 (enExample) |
| DE (1) | DE60215699T2 (enExample) |
| ES (1) | ES2274111T3 (enExample) |
| WO (1) | WO2003051878A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885722B1 (en) | 2005-05-19 | 2011-11-16 | Merck Canada Inc. | Quinoline derivatives as ep4 antagonists |
| MX2007015711A (es) | 2005-07-13 | 2008-02-21 | Sca Hygiene Prod Ab | Articulo absorbente que tiene ajuste mejorado. |
| MX2007015833A (es) | 2005-07-13 | 2008-04-09 | Sca Hygiene Prod Ab | Articulo absorbente que tiene ajuste mejorado. |
| GB2439719A (en) | 2006-07-05 | 2008-01-09 | Sca Hygiene Prod Ab | Absorbent article with differing core density regions |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| CA2734029C (en) * | 2007-08-30 | 2016-03-29 | The Trustees Of Tufts College | Methods for determining the concentration of an analyte in solution |
| UA113831C2 (xx) | 2008-07-31 | 2017-03-27 | Способи і проміжні сполуки для одержання підсилювачів солодкого смаку | |
| JP2015178457A (ja) * | 2012-07-25 | 2015-10-08 | 杏林製薬株式会社 | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 |
| KR20200028050A (ko) | 2012-08-06 | 2020-03-13 | 피르메니히 인코포레이티드 | 단맛 향미 개질제 |
| JO3155B1 (ar) | 2013-02-19 | 2017-09-20 | Senomyx Inc | معدِّل نكهة حلوة |
| CN103319403B (zh) * | 2013-05-10 | 2016-03-30 | 重庆理工大学 | 一种肿瘤血管新生抑制剂己啉酮及其制备方法和用途 |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015050379A1 (ko) * | 2013-10-01 | 2015-04-09 | 광주과학기술원 | 신규한 퀴놀리논 유도체 및 이의 용도 |
| CN103664777A (zh) * | 2013-10-09 | 2014-03-26 | 重庆理工大学 | 一种美啉醇化合物、制备方法及其药物组合物和用途 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN103755697B (zh) * | 2014-01-14 | 2015-08-05 | 湖南大学 | 3-[[2-(2-苄亚氨基)噻唑-5-基]甲基]喹啉-2(1h)-酮及其制备与应用 |
| CN103739599B (zh) * | 2014-01-15 | 2015-10-07 | 湖南大学 | 3-[[2-(2-苄亚肼基)噻唑-5-基]甲基]喹啉-2(1h)-酮及其制备与应用 |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CN104628717B (zh) * | 2015-03-16 | 2017-02-15 | 湖南大学 | 3‑[5‑(1，2，4‑三唑‑1‑基)噻唑‑2‑基]苯并噁嗪及其应用 |
| CN105541827B (zh) * | 2016-02-16 | 2018-01-19 | 湖南大学 | 苄亚肼基噻唑基甲基喹啉酮衍生物及其作为抗癌药的应用 |
| CN105753857B (zh) * | 2016-02-16 | 2018-05-22 | 湖南大学 | 苄亚氨基噻唑甲基喹啉酮衍生物的医药用途 |
| CN105777739B (zh) * | 2016-02-23 | 2018-05-08 | 湖南大学 | 萘氨基噻唑甲基喹啉酮衍生物及其医药用途 |
| EP3814344B1 (en) | 2018-08-07 | 2024-07-24 | Firmenich Incorporated | 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07110853B2 (ja) * | 1990-09-07 | 1995-11-29 | シェリング・コーポレーション | 抗ウイルス化合物および抗高血圧化合物 |
| US5378694A (en) * | 1990-09-07 | 1995-01-03 | Schering Corporation | Acyl and alkoxy substituted quinolines |
| DE19613591A1 (de) * | 1996-04-04 | 1997-10-09 | Hoechst Ag | Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US6265421B1 (en) * | 1997-06-25 | 2001-07-24 | Orion Corporation | Phospholamban inhibitors and a method for increasing coronary flow |
| ATE354569T1 (de) * | 1998-12-04 | 2007-03-15 | Bristol Myers Squibb Co | 3-substituierte-4-arylchinolin-2-on derivate als kaliumkanal- modulatoren |
-
2002
- 2002-12-11 ES ES02784961T patent/ES2274111T3/es not_active Expired - Lifetime
- 2002-12-11 JP JP2003552762A patent/JP2005520797A/ja active Pending
- 2002-12-11 AT AT02784961T patent/ATE343577T1/de not_active IP Right Cessation
- 2002-12-11 AU AU2002350315A patent/AU2002350315B2/en not_active Ceased
- 2002-12-11 DE DE60215699T patent/DE60215699T2/de not_active Expired - Fee Related
- 2002-12-11 CA CA002469048A patent/CA2469048A1/en not_active Abandoned
- 2002-12-11 US US10/498,084 patent/US7348433B2/en not_active Expired - Fee Related
- 2002-12-11 WO PCT/CA2002/001914 patent/WO2003051878A1/en not_active Ceased
- 2002-12-11 EP EP02784961A patent/EP1458718B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005520797A5 (enExample) | ||
| JP4629104B2 (ja) | ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤 | |
| TW202446772A (zh) | Ｓｔｉｎｇ促效化合物 | |
| HUP0200409A2 (en) | Valdecoxib compositions, process for their preparation and their use | |
| CA2468517A1 (en) | Thioether substituted imidazoquinolines | |
| CZ20023794A3 (cs) | Použití kompozice obsahující celecoxib pro rychlou úlevu od bolesti | |
| TW200803844A (en) | Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions | |
| JP2003513961A (ja) | シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物 | |
| JP2013531070A5 (enExample) | ||
| CZ299623B6 (cs) | Rekonstituovatelný selektivne COX-2 inhibující farmaceutický prostredek, zpusob jeho prípravy, injekcní roztok a farmaceutický výrobek | |
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| JP4994618B2 (ja) | Ｔｓ−１／カンプトテシン類による化学放射線療法 | |
| US20060217431A1 (en) | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | |
| US9079876B2 (en) | Imidazole derivatives and preparation method and use thereof | |
| WO2005074930A1 (en) | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids | |
| WO2002078705A1 (en) | Hsp inductor | |
| ES2350452T3 (es) | Formulación parenteral de aceclofenaco líquido no acuoso. | |
| TW201716064A (zh) | 供治療癌症之口服投予紫杉醇及Ｐ－ｇｐ抑制劑的治療性組合 | |
| JP2005510468A5 (enExample) | ||
| US9084769B2 (en) | Compositions comprising non steroidal anti-inflammatory drugs and methods for use thereof | |
| AU2004212337A1 (en) | Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders | |
| JP2009502934A5 (enExample) | ||
| TW200914009A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cranial traumas | |
| US20080096927A1 (en) | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | |
| JP2008543770A (ja) | （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，６−ジクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン |